Levicept
Develops a non-opioid biologic treatment for osteoarthritis pain for patients with painful joint disease
Highlights
- New on EvolcAdded 2026-10-31
About Levicept
Levicept is a clinical-stage biotechnology company developing LEVI-04, a biologic treatment for osteoarthritis pain. The treatment is designed to alter neurotrophin balance and may also help restore joint health.
The company focuses on patients with osteoarthritis. LEVI-04 has completed Phase II trials, and the company reports backing from Medicxi, Pfizer Ventures, Gilde Healthcare and Advent Life Sciences.
Levicept was founded in 2012 and is headquartered in Sandwich, United Kingdom.
Product: LEVI-04, a biologic drug candidate for osteoarthritis pain.
Jobs at Levicept
No open positions listed right now.
Leadership
- Simon Westbrook · Founder and CSOSource: company website
- Eliot Forster · CEOSource: company website
- Darlene Deptula-Hicks · CFOSource: company website
More biotech & pharma companies
LGC Group
Reference materials, diagnostic quality controls and analytical standards for labs and life-science companiesNew on EvolcLibero Pharma
Develops transdermal naltrexone patches for patients with addiction, fibromyalgia and Crohn’s diseaseNew on EvolcLightcast Discovery
Single-cell functional screening platform for antibody and drug discovery teams in biotech and pharma researchNew on EvolcLiminal Biosciences
Develops small-molecule therapeutics for metabolic, inflammatory and fibrotic diseases through GPCR pathwaysNew on EvolcLindus Health
Clinical development of in-licensed drug assets for biotech and pharma partners, run on an AI clinical trial platformNew on EvolcRemote-friendlyMacomics
Macrophage-directed drugs that clear large disease protein complexes, first targeting IgA nephropathy patientsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- WordPress
- jQuery
- nginx